Novo Nordisk to present low-dose CagriSema trial results at ObesityWeek 2026
NVO•Novo Nordisk will present obesity research across 26 abstracts at ObesityWeek 2026, held November 14-17 in Washington, D.C. Presentations include studies of lower-dose CagriSema, Wegovy and investigational semaglutide injections for children ages 6 to under 12.
1. Research presentations
Novo Nordisk plans to present 26 obesity research abstracts at ObesityWeek 2026. CagriSema presentations will examine weight loss at lower doses in REDEFINE 9 and weight-related quality of life in REDEFINE 1; Wegovy studies will cover real-world weight outcomes, food noise and patient experience with oral and injectable treatments. Full STEP Young results on investigational semaglutide injections for children ages 6 to under 12 will be presented with simultaneous publication.
